Clinical Trials Logo

Osteoporosis clinical trials

View clinical trials related to Osteoporosis.

Filter by:

NCT ID: NCT03051620 Recruiting - Osteoporosis Clinical Trials

Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate

PROSA
Start date: February 1, 2017
Phase: N/A
Study type: Observational

The study is a cohort study comprising 140 patients with osteoporosis stopping treatment with alendronate. The study will contribute with new knowledge about biochemical markers of bone turnover as predictors of bone loss after stopping treatment with alendronate.

NCT ID: NCT03040765 Not yet recruiting - Osteoporosis Clinical Trials

Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis

DOHA
Start date: April 1, 2017
Phase: Phase 3
Study type: Interventional

This study is to compare the two medications Denosumab and Zoledronic Acid For Patients With Beta Thalassemia Major Induced Osteoporosis. Patients with B-thalassemia major induce osteoporosis will undergo baseline assessment of the bone densitometry by Dual-energy X-ray absorptiometry scan as a standard of care by the radiology department, then a blood test for bone specific Alkaline phosphatase and type-1 Carboxy Telopeptide will be measured by the chemistry lab. Patients with B-Thalassemia Major induced osteoporosis, who are 18 years of age or more and willing to participate in the study will be enrolled after consenting by the primary investigator in hematology outpatient clinic. Patients with osteoporosis will receive one of the two medications, at the end of the year Dual-energy X-ray absorptiometry scan will be done to compare the response of the two medications. The potential risks include the drug-related side effects

NCT ID: NCT03040531 Recruiting - Clinical trials for Osteoporosis, Steroid Induced

Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis

Start date: January 19, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Prolonged glucocorticoid therapy affects bone fragility, cardiovascular health, glucidic and lipidic metabolism, thyroid and brain function. Glucocorticoid-induced osteoporosis is characterized by low bone turnover and fractures, which occur in 30-50% of patients. Glucocorticoids affect predominantly cancellous or trabecular bone, increasing the risk of vertebral fractures, which may be asymptomatic and occur early during the first months of glucocorticoid treatment. Genistein exerts biological effects by several potential mechanisms. Besides protective effects on bone loss, genistein reduces cardiovascular risk markers, improves endothelial function and ameliorates glucose and lipid metabolism. This study is aimed at demonstrating genistein efficacy in glucocorticoid-induced osteoporosis in a cohort of caucasian post-menopausal women.

NCT ID: NCT03029442 Not yet recruiting - Spinal Cord Injury Clinical Trials

The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury

Start date: April 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the usefulness of a drug, denosumab, to prevent the loss of bone in participants legs due to SCI. This drug is FDA approved to treat osteoporosis in women after menopause who have an increased risk for fractures, to treat women receiving certain treatments for breast cancer who have an increased risk of fractures, and to treat bone loss in men receiving certain treatments for prostate cancer who have increased risk for fractures. This drug is considered experimental for the purpose of this study. Study participation will last for approximately 12 months (6 study visits total), visits will range from1-4.5 hours depending on the number of tests that need to be completed. The study is a double-blinded placebo trail in which the participant will be randomly assigned to on of two groups, Denosumab injections or placebo - inactive salt solution injections.

NCT ID: NCT03026660 Completed - Clinical trials for Postmenopausal Osteoporosis

Moringa Oleifera on Bone Density

Start date: July 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effects of Moringa Oleifera on the structure and function of bone in post-menopausal women ingesting 1000 mg of Moringa Oleifera daily for 12 weeks.

NCT ID: NCT03006003 Not yet recruiting - Depressive Syndrome Clinical Trials

Osteoporosis Treatment in Post-menopausal Women

Start date: December 2016
Phase: Phase 4
Study type: Interventional

The study will be conducted to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.

NCT ID: NCT03005678 Not yet recruiting - Osteoporosis Clinical Trials

Denosumab Versus Bisphosphonates (Alendronate) in GIOP

Start date: April 2017
Phase: Phase 4
Study type: Interventional

A randomized controlled trial to compare for the efficacy and tolerability of denosumab and oral alendronate in the management of glucocorticoid induced osteoporosis

NCT ID: NCT03002428 Recruiting - Osteoporosis Clinical Trials

A Comparison of PF708 and Forteo in Osteoporosis Patients

Start date: December 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effects of two teriparatide products, PF708 and Forteo, in patients with osteoporosis.

NCT ID: NCT02981732 Active, not recruiting - Clinical trials for Postmenopausal Osteoporosis

CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome

PMOP
Start date: October 2016
Phase: N/A
Study type: Interventional

For nearly 112 million patients with osteoporosis in China, it is of great significance for preventing and treating by clearly understanding the molecular mechanism of kidney deficiency. Thus, the research group has demonstrated in the earlier research that CLCF1 is an associated gene that can regulate JAK2/STAT3 signal pathway and impact bone metabolism for kidney yin deficiency of postmenopausal osteoporosis (PMOP). To make clear understanding of the direct-acting mechanism of CLCF1 for bone metabolism, this study intends to: ①observe impacts of low expression of CLCF1 upon immunities in mice and OPG/RANKL/RANK signal system using the technology of adenovirus associated virus. ②explore impacts of over-expression and silencing of CLCF1 on B lymphocytes by culcuturing the cells together with osteoblasts. ③ analyze the impacts of treating kidney yin deficiency of PMOP by Liuwei Dihuang pill upon immunities and OPG/RANKL/RANK system, and discuss the mechanism of regulating bone metabolism by CLCF1 by OPG/RANKL/RANK system via the bridge between immune system and bone metabolism, so as to demonstrate if the hypothesis of this study that "the molecular osteoimmunological mechanism of kidney yin deficiency of postmenopausal osteoporosis (PMOP) is possibly closely related to the impacts of CLCF1 regulation of OPG/RANKL/RANK signal system on bone metabolism" is right or not.

NCT ID: NCT02977949 Recruiting - Clinical trials for Selective Estrogen Receptor Modulator (SERM)

The Effects of Seasonal Changes in Osteoporosis Treatment

Start date: January 2012
Phase: N/A
Study type: Observational [Patient Registry]

There are few reports concerning to the seasonal variation of osteoporosis treatment. In this study, we plan to compare clinical efficacy and safety by seasons.